Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialYung‐Jue Bang, Yoon‐Koo Kang, Eric Van Cutsem et al.|The Lancet|2010Cited by 7.3k
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trialIan Smith, Martine Piccart, Aron Goldhirsch et al.|The Lancet|2007Cited by 1.5k
Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM StudyBella Kaufman, Alison Jones, John R. Mackey et al.|Journal of Clinical Oncology|2009Cited by 850